1. Selenoprotein P; P for Plasma, Prognosis, Prophylaxis, and More
- Author
-
Yoshiro Saito and Ryouhei Tsutsumi
- Subjects
0301 basic medicine ,congenital, hereditary, and neonatal diseases and abnormalities ,medicine.medical_specialty ,Pharmaceutical Science ,chemistry.chemical_element ,behavioral disciplines and activities ,03 medical and health sciences ,chemistry.chemical_compound ,Plasma ,Selenium ,0302 clinical medicine ,Internal medicine ,Selenoprotein P ,medicine ,Animals ,Humans ,Pharmacology ,Pulmonary Arterial Hypertension ,Selenocysteine ,business.industry ,musculoskeletal, neural, and ocular physiology ,Type 2 Diabetes Mellitus ,General Medicine ,Prognosis ,body regions ,030104 developmental biology ,Endocrinology ,chemistry ,Diabetes Mellitus, Type 2 ,030220 oncology & carcinogenesis ,population characteristics ,business ,Biomarkers - Abstract
Selenoprotein P (SeP) is one of the 25 human selenocysteine (Sec)-containing proteins, and is generally thought to function as a plasma carrier of the trace element selenium in the body. Recent studies, however, indicate unsuspected pivotal roles of SeP in human diseases, particularly in type 2 diabetes mellitus (T2DM) and pulmonary arterial hypertension (PAH). In this review, we will summarize the characteristics of SeP and recent advances in the field, especially focusing on the emerging roles of SeP in pathophysiological conditions. We will also discuss potential medical/pharmaceutical applications targeting SeP.
- Published
- 2020